Effect of inactivated whole-virion concentrated purified vaccine for the prevention of COVID-19 on clinical and biochemical blood parameters of immature rats
Introduction. The prevalence of new coronavirus infection (COVID-19) in 2021-2022 in the pediatric population was 9.5%, and fatal outcomes began to be recorded. In 2022–2023, the proportion of children infected with COVID-19 increased to 18%. Developing a vaccine for the pediatric population is an u...
Saved in:
| Main Authors: | , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Central Research Institute for Epidemiology
2025-04-01
|
| Series: | Вопросы вирусологии |
| Subjects: | |
| Online Access: | https://virusjour.crie.ru/jour/article/viewFile/16728/971 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849710723601530880 |
|---|---|
| author | Aleksandra A. Siniugina Natalya A. Lycheva Anastasia A. Saprykina Kirill L. Kryshen’ Vasiliy D. Apolokhov Anastasiya D. Chernavtseva Anastasiya A. Kovpak Yuriy Yu. Ivin Anastasia N. Piniaeva Marina N. Makarova Valery G. Makarov Aidar A. Ishmukhametov |
| author_facet | Aleksandra A. Siniugina Natalya A. Lycheva Anastasia A. Saprykina Kirill L. Kryshen’ Vasiliy D. Apolokhov Anastasiya D. Chernavtseva Anastasiya A. Kovpak Yuriy Yu. Ivin Anastasia N. Piniaeva Marina N. Makarova Valery G. Makarov Aidar A. Ishmukhametov |
| author_sort | Aleksandra A. Siniugina |
| collection | DOAJ |
| description | Introduction. The prevalence of new coronavirus infection (COVID-19) in 2021-2022 in the pediatric population was 9.5%, and fatal outcomes began to be recorded. In 2022–2023, the proportion of children infected with COVID-19 increased to 18%. Developing a vaccine for the pediatric population is an urgent task.
The aim of the study is to explore the effect of the vaccine on the parameters of general and biochemical blood tests in immature rats.
Materials and methods. The study was performed on 112 immature rats (60 females, 52 males) of the Wistar line. Animals were randomized into groups that received the CoviVac vaccine at doses of 0.125, 0.25 and 0.5 mL/animal or placebo (0.5 mL/animal), intramuscularly on days 1, 15, 29 and 43 of the experiment. General and biochemical blood tests were performed twice, on the 57th and 71st days.
Results. Oligocythemia (0.25 and 0.5 mL/animal, p 0.05), leukocytosis and thrombocytopenia (0.5 mL/animal, p 0.05) were recorded in males. Monocytopenia (0.5 mL/animal, p 0.05) and leukopenia (0.25 mL/animal, p 0.05) were established in females. In males, an increase in the amount of globulins and total protein (0.5 mL/animal), a decrease in the A/G ratio (doses 0.25 and 0.5 mL/animal), a decrease in the cholesterol level (0.125 mL/animal) were detected. In females, an increase in the amount of albumin and total protein (0.5 mL/animal, p 0.05), a decrease in the level of triglycerides (0.125, 0.25, 0.5 mL/animal, placebo, p 0.05), a decrease in the level of lactate dehydrogenase, triglycerides and urea (0.25 mL/animal, p 0.05) were recorded.
Conclusion. The safety of the CociVac vaccine in relation to clinical and biochemical blood parameters has been demonstrated. |
| format | Article |
| id | doaj-art-810e8035b18d4692a75050e44da7cf53 |
| institution | DOAJ |
| issn | 0507-4088 2411-2097 |
| language | English |
| publishDate | 2025-04-01 |
| publisher | Central Research Institute for Epidemiology |
| record_format | Article |
| series | Вопросы вирусологии |
| spelling | doaj-art-810e8035b18d4692a75050e44da7cf532025-08-20T03:14:50ZengCentral Research Institute for EpidemiologyВопросы вирусологии0507-40882411-20972025-04-0170217718810.36233/0507-4088-3031273Effect of inactivated whole-virion concentrated purified vaccine for the prevention of COVID-19 on clinical and biochemical blood parameters of immature ratsAleksandra A. Siniugina0https://orcid.org/0000-0002-7251-6570Natalya A. Lycheva1https://orcid.org/0000-0002-5842-5728Anastasia A. Saprykina2https://orcid.org/0000-0002-7588-3982Kirill L. Kryshen’3https://orcid.org/0000-0003-1451-7716Vasiliy D. Apolokhov4https://orcid.org/0000-0002-9978-222XAnastasiya D. Chernavtseva5https://orcid.org/0009-0009-6232-7512Anastasiya A. Kovpak6https://orcid.org/0000-0003-3200-763XYuriy Yu. Ivin7https://orcid.org/0000-0003-0995-7944Anastasia N. Piniaeva8https://orcid.org/0000-0001-5381-2393Marina N. Makarova9https://orcid.org/0000-0003-3176-6386Valery G. Makarov10https://orcid.org/0000-0002-2447-7888Aidar A. Ishmukhametov11https://orcid.org/0000-0001-6130-4145Chumakov Federal Scientific Center for Research and Development of Immune-and-Biological Products of Russian Academy of Sciences (Institute of Poliomyelitis), Village of Institute of PoliomyelitisChumakov Federal Scientific Center for Research and Development of Immune-and-Biological Products of Russian Academy of Sciences (Institute of Poliomyelitis), Village of Institute of PoliomyelitisResearch-and-manufacturing company «HOME OF PHARMACY» Joint Stock companyResearch-and-manufacturing company «HOME OF PHARMACY» Joint Stock companyChumakov Federal Scientific Center for Research and Development of Immune-and-Biological Products of Russian Academy of Sciences (Institute of Poliomyelitis), Village of Institute of PoliomyelitisChumakov Federal Scientific Center for Research and Development of Immune-and-Biological Products of Russian Academy of Sciences (Institute of Poliomyelitis), Village of Institute of PoliomyelitisChumakov Federal Scientific Center for Research and Development of Immune-and-Biological Products of Russian Academy of Sciences (Institute of Poliomyelitis), Village of Institute of PoliomyelitisChumakov Federal Scientific Center for Research and Development of Immune-and-Biological Products of Russian Academy of Sciences (Institute of Poliomyelitis), Village of Institute of PoliomyelitisChumakov Federal Scientific Center for Research and Development of Immune-and-Biological Products of Russian Academy of Sciences (Institute of Poliomyelitis), Village of Institute of PoliomyelitisResearch-and-manufacturing company «HOME OF PHARMACY» Joint Stock companyResearch-and-manufacturing company «HOME OF PHARMACY» Joint Stock companyChumakov Federal Scientific Center for Research and Development of Immune-and-Biological Products of Russian Academy of Sciences (Institute of Poliomyelitis), Village of Institute of PoliomyelitisIntroduction. The prevalence of new coronavirus infection (COVID-19) in 2021-2022 in the pediatric population was 9.5%, and fatal outcomes began to be recorded. In 2022–2023, the proportion of children infected with COVID-19 increased to 18%. Developing a vaccine for the pediatric population is an urgent task. The aim of the study is to explore the effect of the vaccine on the parameters of general and biochemical blood tests in immature rats. Materials and methods. The study was performed on 112 immature rats (60 females, 52 males) of the Wistar line. Animals were randomized into groups that received the CoviVac vaccine at doses of 0.125, 0.25 and 0.5 mL/animal or placebo (0.5 mL/animal), intramuscularly on days 1, 15, 29 and 43 of the experiment. General and biochemical blood tests were performed twice, on the 57th and 71st days. Results. Oligocythemia (0.25 and 0.5 mL/animal, p 0.05), leukocytosis and thrombocytopenia (0.5 mL/animal, p 0.05) were recorded in males. Monocytopenia (0.5 mL/animal, p 0.05) and leukopenia (0.25 mL/animal, p 0.05) were established in females. In males, an increase in the amount of globulins and total protein (0.5 mL/animal), a decrease in the A/G ratio (doses 0.25 and 0.5 mL/animal), a decrease in the cholesterol level (0.125 mL/animal) were detected. In females, an increase in the amount of albumin and total protein (0.5 mL/animal, p 0.05), a decrease in the level of triglycerides (0.125, 0.25, 0.5 mL/animal, placebo, p 0.05), a decrease in the level of lactate dehydrogenase, triglycerides and urea (0.25 mL/animal, p 0.05) were recorded. Conclusion. The safety of the CociVac vaccine in relation to clinical and biochemical blood parameters has been demonstrated.https://virusjour.crie.ru/jour/article/viewFile/16728/971covid-19new coronavirus infectionsafetyvaccinecocivacimmature rats |
| spellingShingle | Aleksandra A. Siniugina Natalya A. Lycheva Anastasia A. Saprykina Kirill L. Kryshen’ Vasiliy D. Apolokhov Anastasiya D. Chernavtseva Anastasiya A. Kovpak Yuriy Yu. Ivin Anastasia N. Piniaeva Marina N. Makarova Valery G. Makarov Aidar A. Ishmukhametov Effect of inactivated whole-virion concentrated purified vaccine for the prevention of COVID-19 on clinical and biochemical blood parameters of immature rats Вопросы вирусологии covid-19 new coronavirus infection safety vaccine cocivac immature rats |
| title | Effect of inactivated whole-virion concentrated purified vaccine for the prevention of COVID-19 on clinical and biochemical blood parameters of immature rats |
| title_full | Effect of inactivated whole-virion concentrated purified vaccine for the prevention of COVID-19 on clinical and biochemical blood parameters of immature rats |
| title_fullStr | Effect of inactivated whole-virion concentrated purified vaccine for the prevention of COVID-19 on clinical and biochemical blood parameters of immature rats |
| title_full_unstemmed | Effect of inactivated whole-virion concentrated purified vaccine for the prevention of COVID-19 on clinical and biochemical blood parameters of immature rats |
| title_short | Effect of inactivated whole-virion concentrated purified vaccine for the prevention of COVID-19 on clinical and biochemical blood parameters of immature rats |
| title_sort | effect of inactivated whole virion concentrated purified vaccine for the prevention of covid 19 on clinical and biochemical blood parameters of immature rats |
| topic | covid-19 new coronavirus infection safety vaccine cocivac immature rats |
| url | https://virusjour.crie.ru/jour/article/viewFile/16728/971 |
| work_keys_str_mv | AT aleksandraasiniugina effectofinactivatedwholevirionconcentratedpurifiedvaccineforthepreventionofcovid19onclinicalandbiochemicalbloodparametersofimmaturerats AT natalyaalycheva effectofinactivatedwholevirionconcentratedpurifiedvaccineforthepreventionofcovid19onclinicalandbiochemicalbloodparametersofimmaturerats AT anastasiaasaprykina effectofinactivatedwholevirionconcentratedpurifiedvaccineforthepreventionofcovid19onclinicalandbiochemicalbloodparametersofimmaturerats AT kirilllkryshen effectofinactivatedwholevirionconcentratedpurifiedvaccineforthepreventionofcovid19onclinicalandbiochemicalbloodparametersofimmaturerats AT vasiliydapolokhov effectofinactivatedwholevirionconcentratedpurifiedvaccineforthepreventionofcovid19onclinicalandbiochemicalbloodparametersofimmaturerats AT anastasiyadchernavtseva effectofinactivatedwholevirionconcentratedpurifiedvaccineforthepreventionofcovid19onclinicalandbiochemicalbloodparametersofimmaturerats AT anastasiyaakovpak effectofinactivatedwholevirionconcentratedpurifiedvaccineforthepreventionofcovid19onclinicalandbiochemicalbloodparametersofimmaturerats AT yuriyyuivin effectofinactivatedwholevirionconcentratedpurifiedvaccineforthepreventionofcovid19onclinicalandbiochemicalbloodparametersofimmaturerats AT anastasianpiniaeva effectofinactivatedwholevirionconcentratedpurifiedvaccineforthepreventionofcovid19onclinicalandbiochemicalbloodparametersofimmaturerats AT marinanmakarova effectofinactivatedwholevirionconcentratedpurifiedvaccineforthepreventionofcovid19onclinicalandbiochemicalbloodparametersofimmaturerats AT valerygmakarov effectofinactivatedwholevirionconcentratedpurifiedvaccineforthepreventionofcovid19onclinicalandbiochemicalbloodparametersofimmaturerats AT aidaraishmukhametov effectofinactivatedwholevirionconcentratedpurifiedvaccineforthepreventionofcovid19onclinicalandbiochemicalbloodparametersofimmaturerats |